AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$WGS

Stueland Katherine sold $311K of WGS

Stueland Katherine (CHIEF EXECUTIVE OFFICER) sold 3,692 shares of GeneDx Holdings Corp. (WGS) at $84.22 ($0.31M total) on 2026-09-09.

Original reporting
SEC EDGAR · Stueland Katherine
Published Sep 11, 2026, 8:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 8:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$WGS
Neutral
medium confidence
Mentioned
$WGS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$WGSNeutralLow
01

Why it matters

While the transaction size is modest, it provides the first public insight into insider sentiment for GeneDx.

02

Market read

The filing offers a fresh data point for traders monitoring insider activity, but its material impact is limited.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 4/10Novelty 4/10Timing: filing disclosed on 2026-09-11

Background

Form 4 filings disclose insider transactions; this filing reports a CEO's open-market sale.

Company-level read

Ticker impact

$WGSNeutralMedium confidence
Context

CEO Katherine Stueland sold 3,692 shares of GeneDx Holdings for $310,932, reducing her stake to 107,227 shares.

Expected impact

Potential slight downward pressure on WGS price in the short term.

Evidence & confidence

Insider sales of this size are common and rarely move the stock dramatically, but the CEO's sale could be noted by traders.

Market effects

Sector

Minimal impact on the broader genetic testing sector.

Regional

No significant regional effect.

Global

Limited relevance beyond the individual stock.

Counterpoint

What could challenge this read

The sale may be unrelated to company fundamentals and could be a routine liquidity move.

Key entities

  • Company
    GeneDx Holdings Corp.

    Genetic testing and diagnostics firm (ticker WGS).

  • Executive
    Katherine Stueland

    Chief Executive Officer of GeneDx.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

WGS insider trading history →

Related articles

AUG 14
MedAI 8/10

GeneDx (WGS) Q2 2026 Earnings Call Transcript

GeneDx reported Q2 2026 revenue of $114.4 million, up 11% year over year, with exome and genome revenue of $100.3 million (+17%). Adjusted net income was $0.4 million and adjusted diluted EPS $0.01. Q3 revenue guidance is $122 million to $124 million, and full-year 2026 revenue guidance is $475 million to $490 million.

aol.com6 min
AUG 3
$PLTRMed

After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR

Investing.com’s after-hours movers report highlights Palantir (PLTR) up 10% after Q2 EPS of $0.41 and $1.94B revenue, with 2026 revenue guidance raised to $8.15–$8.158B. Snap (SNAP) rose 9.6% on Q2 revenue $1.6B and Q3 guidance $1.7–$1.74B. Backblaze (BLZE) gained 16% on Q2 beat and raised 2026 revenue to $172–$174M. ON (ON) +5%, ICHR -11%, WGS -7%, WHR -4%.

investing.com6 min
AUG 3
$WGSHighAI 9/10

GeneDx Holdings Corp. (WGS): Results of Operations and Financial Condition

GeneDx Holdings Corp. (WGS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 GeneDx Reports Second Quarter 2026 Financial Results • Reported second quarter 2026 revenue of $114.4 million, including $100.3 million in exome and genome revenue • Reported exome and genome volume growth of 32% year-over-year • Reported adjusted gross margin (1) of

SEC EDGAR 8-K6 min
JUL 28
$WGSMed

GeneDx’s $4.8M AI-Hype Settlement Exposes Governance Failures -By Fransiscus Nanga Roka

GeneDx Holdings (formerly Sema4, NASDAQ: WGS) and former officers filed responses in a federal securities class action over alleged overstated capabilities of Centrellis, an AI-molecular and phenotypic data system. The parties settled for about $4.8M to resolve claims of fraud tied to a 2022 GeneDx acquisition valued near $623M. Court filings were submitted July 24, 2026.

opinionnigeria.com5 min
JUL 18
$WGSMed

GeneDx Holdings Corp. (WGS) Investors: August 3, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP

Kessler Topaz Meltzer & Check said a securities-fraud class action was filed against GeneDx Holdings Corp. (NASDAQ: WGS) in the District of Connecticut. The class period runs April 16, 2025 to May 4, 2026, with an Aug. 3, 2026 lead-plaintiff deadline. Allegations center on statements about the viability of GeneDx’s up-to-$51 million acquisition of Fabric Genomics and a May 4, 2026 impairment write-off of $31.3 million.

prnewswire.com4 min